검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | M7824 |
Overview Company | EMD Serono Research & Development Institute, Inc. |
Overview Modality | ADC |
Overview Target | HER2 |
Overview Indication | Non-small Cell Lung Cancer |
Overview Phase | PHASE_3 |
Overview Status | DISCONTINUED |
MoA Mechanism | targeting PD-L1 and TGF-β pathway |
MoA Biomarker | PD-L1-positive |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | The establishment of B cell-deficient Igh-J KO mouse model by gene editing and efficacy evaluation.. Over the last few years, immunotherapy has made significant progress in treating various cancers with therapeutic antibodies. However, therapeutic antibodies have been validated for inducing an unintended immune response in human and animal models, which leads to the emergence of anti-drug antibodi… |
Clinical Primary efficacy | ORR 62.5% |
Clinical ORR | 62.5% |
Clinical Result source | ClinicalTrials.gov NCT05012098 |
Clinical Data Tier / Score | A · 41 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | M7824 |
Overview Company | EMD Serono Research & Development Institute, Inc. |
Overview Modality | ADC |
Overview Target | HER2 |
Overview Indication | Non-small Cell Lung Cancer |
Overview Phase | PHASE_3 |
Overview Status | DISCONTINUED |
MoA Mechanism | targeting PD-L1 and TGF-β pathway |
MoA Biomarker | PD-L1-positive |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | The establishment of B cell-deficient Igh-J KO mouse model by gene editing and efficacy evaluation.. Over the last few years, immunotherapy has made significant progress in treating various cancers with therapeutic antibodies. However, therapeutic antibodies have been validated for inducing an unintended immune response in human and animal models, which leads to the emergence of anti-drug antibodi… |
Clinical Primary efficacy | ORR 62.5% |
Clinical ORR | 62.5% |
Clinical Result source | ClinicalTrials.gov NCT05012098 |
Clinical Data Tier / Score | A · 41 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교